Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-29T18:11:05.476Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of probiotic supplement Lactobacillus Plantarum CECT7485 and Lactobacillus Brevis CECT7480 on sleep quality in patients with anxiety and depression comorbidity

Published online by Cambridge University Press:  19 July 2023

Y. Denysov ,
G. Putyatin ,
S. Moroz  and
V. Semenikhina
Y. Denysov*
Affiliation:
Psychiatry, psychotherapy, addictology and medical psychology, Donetsk national medical university, Kropyvnitskyi
G. Putyatin
Affiliation:
Psychiatry, psychotherapy, addictology and medical psychology, Donetsk national medical university, Kropyvnitskyi
S. Moroz
Affiliation:
Psychiatry, Municipal Enterprise “Dnipro Multiprofile Clinical Hospital for the Provision of Psychiaric Care of Dnipropetrovsk Regional Council”, Dnipro, Ukraine
V. Semenikhina
Affiliation:
Psychiatry, Municipal Enterprise “Dnipro Multiprofile Clinical Hospital for the Provision of Psychiaric Care of Dnipropetrovsk Regional Council”, Dnipro, Ukraine
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Recent studies have supported that Lactobacillus plantarum can reduce the severity of anxiety and depression. However, previous studies did not focus on the sleep quality. This study determines whether Lactobacillus Plantarum CECT7485 and Lactobacillus Brevis CECT7480 reduce the severity of insomnia, and improves sleep quality in patients who comorbidity of depression and anxiety disorders.

Objectives

An assessment of insomniac effects a probiotic supplement containing Lactobacillus Plantarum CECT7485 and Lactobacillus Brevis CECT7480 (PLANTARUM) in patients with anxiety and depression comorbidity undergoing treatment with selective serotonin reuptake inhibitors (SSRI) antidepressants.

Methods

Sixty patients with mixed anxiety and depressive disorder (according to ICD-10 diagnostic criteria F41.2) were included in an 8-week open label study. Thirty participants received either SSRI antidepressants with PLANTARUM at a dose of 1.0 × 109 CFU once per day and thirty patients received SSRI antidepressants only. The severity of insomnia was assessed using Insomnia Severity Index (ISI). The severity of depressive symptoms was rated using Hamilton Depressive Rating Scale (HDRS). The severity of anxiety symptoms was assessed using Hamilton Anxiety Rating Scale (HAM-A) and General Anxiety Disorder Scale (GAD-7).

Results

After 8 weeks intervention, a significant reduction of ISI total score (from 22,1±2,8 to 14,1±2,1) was detected in patients with anxiety and depression who prescribed SSRI antidepressants and PLANTARUM (p˂0,05), compared with participants who didn’t receive probiotics (p>0,05). Also, we detected a significant improve sleep quality of insomniac patients with comorbidity of anxiety and depressive symptoms (p˂0,05) who received SSRI antidepressants and probiotic supplement Lactobacillus Plantarum CECT7485/Lactobacillus Brevis CECT7480.

Conclusions

The present data illustrated that probiotic supplement Lactobacillus Plantarum CECT7485 and Lactobacillus Brevis CECT7480 is a feasible for adjunctive to SSRI antidepressants intervention for insomniac patients with anxiety and depressive comorbidity

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S454
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.